Abstract:BackgroundAfter a 1999 National Cancer Institute (NCI) clinical alert was issued, chemoradiotherapy has become widely used in treating women with cervical cancer. Two subsequent systematic reviews found that interpretation of the benefits was complicated and some important clinical questions were unanswered.ObjectivesWe initiated a meta-analysis seeking updated individual patient data (IPD) from all randomised controlled trials (RCTs) to assess the effect of chemoradiotherapy on all outcomes. We pre-specified analyses to investigate whether the effect of chemoradiotherapy differed by trial or patient characteristics.Search strategyWe supplemented MEDLINE, LILACS and CANCERLIT searches with information from trial registers, by handsearching relevant meeting proceedings and by discussion with relevant trialists and organisations. Searches were updated until October 2009.Selection criteriaBoth published and unpublished trials were eligible for inclusion provided the patients had been randomised between radiotherapy (with or without surgery) versus concomitant chemoradiotherapy (with or without surgery); that the method of randomisation precluded prior knowledge of the treatment to be assigned; and that the trial had completed patient recruitment before the date of the final analyses.Data collection and analysisWe carried out a quantitative meta-analysis using updated information from individual patients from all available RCTs. We sought data from all patients randomised in all eligible trials. We obtained updated information on survival, recurrence and date of last follow up. To avoid potential bias, we requested information for all randomised patients, including those who had been excluded from the investigators' original analyses.Main resultsEighteen trials were identified and 15 of these were eligible for inclusion in the main analysis. On the basis of 13 trials that compared chemoradiotherapy versus the same radiotherapy, there was a 6% improvement in 5-year survival with chemoradiotherapy (hazard ratio (HR) = 0.81, P < 0.001). A larger survival benefit was seen for the two further trials in which chemotherapy was administered after chemoradiotherapy. There was a significant survival benefit for both the group of trials that used platinum-based (HR = 0.83, P = 0.017) and non-platinum based (HR = 0.77, P = 0.009) chemoradiotherapy, but no evidence of a difference in the size of the benefit by radiotherapy or chemotherapy dose or scheduling was seen. Chemoradiotherapy also reduced local and distant recurrence and progression and improved disease-free survival (DFS). There was a suggestion of a difference in the size of the survival benefit with tumour stage, but not across other patient subgroups. Acute haematological and gastro-intestinal toxicity were increased with chemoradiotherapy, but data were too sparse for an analysis of late toxicity.Authors' conclusionsThese results endorse the recommendations of the NCI alert, but also demonstrate their applicability to all women and a benefit of non-platinum based chemoradiotherapy. Furthermore, although these results suggest an additional benefit from adjuvant chemotherapy this requires testing in RCTs.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

Chemotherapy in addition to supportive care improves survival in advanced non–small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 …

Chemotherapy Plus Best Supportive Care Versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: a Meta-Analysis of Randomized Controlled Trials.

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

Resectable non-small cell lung cancer Adjuvant chemotherapy: slightly longer survival

Meta-Analysis Comparing Carboplatin and Cisplatin-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Chemotherapy in elderly (Over 75 years old)lung cancer patients: a retrospective analysis: P2-325

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.

Reducing Uncertainties About The Effects Of Chemoradiotherapy For Cervical Cancer: Individual Patient Data Meta-Analysis

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials

Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer

A Meta Analysis of Gemcitabine Plus Platinum Chemotherapy Compared with Single-agent Chemotherapy in the Treatment of Non-small Cell Lung Cancer

EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis

Curative Effects, Prognostic Factors, and Adverse Reactions of Different Treatment Modalities of Chemotherapy in Patients with Non-Small Cell Lung Cancer

Investigation of the Optimal Platinum-Based Regimen in the Postoperative Adjuvant Chemotherapy Setting for Early-Stage Resected Non-Small Lung Cancer: a Bayesian Network Meta-Analysis

Chemotherapy in Advanced Non-small Cell Lung Cancer: Using Standard Methods of Evidence-based Medicine Treatment

The Efficacy Of Combining Antiangiogenic Agents With Chemotherapy For Patients With Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review And Meta-Analysis

The Optimal Neoadjuvant Regimen for Nonsmall Cell Lung Cancer: A Meta-Analysis

Comparative Analysis of Immune Checkpoint Inhibitors and Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

Chemotherapy Plus Erlotinib Versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis